冠脉搭桥同期房颤外科消融的生存获益:Medicare受益者分析
本研究回顾性分析2008至2019年Medicare数据库中87,699例既往房颤且接受单纯CABG的受益者,其中19,384例(22.2%)同期行外科消融。经倾向评分加权及工具变量分析,同期消融与风险校正中位生存期延长约4.40个月相关,由高频消融外科医生手术亦与生存获益相关,支持现行指南推荐。
要点
- 房颤患者CABG同期外科消融与风险校正中位生存期延长4.40个月相关。
- 由高频消融外科医生行CABG亦与生存获益相关,中位生存期延长4.96个月。
- 当前实践中同期外科消融使用率仅22.2%,存在明显未充分利用。
核心结论
- 在既往房颤的Medicare受益者中,CABG同期外科消融与改善生存相关。
- 由高频消融外科医生行CABG亦与改善生存相关。
- 研究结果支持现行指南推荐房颤患者CABG同期行外科消融,并提示当前实践中消融使用不足。
研究设计与样本
- 回顾性分析Medicare数据,纳入2008至2019年87,699例既往房颤接受CABG(伴或不伴同期外科消融)的受益者。
- 采用重叠倾向评分加权校正已测量混杂因素,并以外科医生消融频率作为工具变量校正未测量混杂因素。
- 全因死亡率和卒中发生率作为独立终点评估。
主要发现
- 87,699例中19,384例(22.2%)接受同期外科消融。
- 按治疗分析,消融组风险校正中位生存期7.82年(95%CI 7.65-7.98) vs 非消融组7.46年(95%CI 7.38-7.57),中位生存获益4.40个月(95%CI 2.40-6.36),P<.001。
- 按医生偏好分析,高频消融医生组风险校正中位生存期7.03年(95%CI 6.90-7.20) vs 低频消融医生组6.62年(95%CI 6.46-6.79),中位生存获益4.96个月(95%CI 2.10-7.82),P<.001。
- 1,193名外科医生低频消融(<5%,16,242例),1,834名偶尔消融(≥5%但<40%,55,820例),652名高频消融(≥40%,15,637例)。
临床怎么用
- 对既往房颤接受CABG的患者,应考虑同期行外科消融以改善生存。
- 当前同期消融使用率仅22.2%,需提高指南推荐措施的落实。
局限性
- 原文未报告卒中终点的具体结果。
- 回顾性设计,尽管采用倾向评分加权和工具变量分析,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite guideline recommendations, use of concomitant surgical ablation during isolated coronary artery bypass grafting (CABG) in patients with preexisting atrial fibrillation is low, with a poorly quantified impact on stroke and survival. METHODS: A retrospective review of Medicare data identified 87,699 beneficiaries with preexisting atrial fibrillation undergoing CABG, with or without concomitant surgical ablation, from 2008 to 2019. All-cause mortality and the incidence of stroke were evaluated as separate end points. Overlap propensity score weighting adjusted for measured confounding variables. Analyses were repeated using surgeon frequency of ablation as an instrumental variable to adjust for unmeasured confounding variables. RESULTS: Of 87,699 beneficiaries with atrial fibrillation undergoing CABG, 19,384 (22.2%) underwent concomitant surgical ablation. During CABG, 1193 surgeons infrequently performed ablation (<5%; 16,242 beneficiaries), 1834 occasionally performed ablation (≥5% but <40%; 55,820 beneficiaries), and 652 frequently performed ablation (≥40%; 15,637 beneficiaries). Beneficiaries undergoing surgical ablation (as-treated analysis) had a risk-adjusted median survival advantage of 4.40 months (95% CI, 2.40-6.36 months; 7.82 years [95% CI, 7.65-7.98 years] vs 7.46 years [95% CI, 7.38-7.57 years]; P < .001 for risk-adjusted survival comparison) compared with those without. Beneficiaries undergoing CABG by surgeons who frequently ablate (provider-preference analysis) had a risk-adjusted median survival advantage of 4.96 months (95% CI, 2.10-7.82 months; 7.03 years [95% CI, 6.90-7.20 years] vs 6.62 years [95% CI, 6.46-6.79 years], P < .001 for risk-adjusted survival comparison) compared with surgeons who infrequently ablate. CONCLUSIONS: In Medicare beneficiaries with preexisting atrial fibrillation, concomitant surgical ablation during CABG is associated with improved survival, as is undergoing CABG by a surgeon who frequently ablates. Our findings support current guidelines recommending surgical ablation during CABG in patients with atrial fibrillation and highlight that ablation is currently underused in contemporary practice.
引用
- Schaffer JM, Kluis A, Squiers JJ, et al. Survival After Surgical Ablation of Atrial Fibrillation During Coronary Artery Bypass in Medicare Beneficiaries. Ann Thorac Surg. 2025. PMID: 40459477. doi:10.1016/j.athoracsur.2025.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。